grant
Curing chronic Toxoplasma infection with novel and potent protease inhibitors
Organization UNIVERSITY OF MICHIGAN AT ANN ARBORLocation ANN ARBOR, UNITED STATESPosted 1 Aug 2025Deadline 31 Jul 2030
NIHUS FederalResearch GrantFY202521+ years oldAIDS/HIVAdultAdult HumanAffectAmericanAntiproteasesAssayBindingBioassayBiological AssayBlindnessBody TissuesCATLCTSL ProteinCathepsin LCell BodyCellsCellular Immune FunctionChronicClinicalCystDevelopmentDiminished VisionDiseaseDisorderDockingDrug KineticsDrugsEndopeptidase InhibitorsEsteroproteasesEyeEye InfectionsEyeballGoalsGrafting ProcedureHIV/AIDSHalf-LifeHealthHumanImplantIn VitroIn vivo analysisIndividualInfectionInformaticsLeadLesionLibrariesLigandsLong-term infectionLow VisionMajor Excreted ProteinMeasuresMedicationMiceMice MammalsModalityModelingModern ManMolecular InteractionMurineMusOcular InfectionsOcular ToxoplasmosisOrgan TransplantationOrgan TransplantsOutcomeParasitesPartial SightPatientsPb elementPeptidase InhibitorsPeptidasesPeptide Hydrolase InhibitorsPeptide HydrolasesPeptide Peptidohydrolase InhibitorsPersonsPharmaceutical PreparationsPharmacokineticsPosterior UveitisPropertyProtease AntagonistsProtease GeneProtease InhibitorProteasesProteinase InhibitorsProteinasesProteolytic EnzymesReceptor ProteinRecurrenceRecurrentReduced VisionRetinaRiskSightSourceStructureStructure-Activity RelationshipSubnormal VisionT gondiiT gondii infectionT. gondiiT. gondii infectionTestingTherapeuticTherapeutic InterventionTissuesToxoplasmaToxoplasma gondiiToxoplasma gondii InfectionToxoplasmosisVisionVisual impairmentWorkadulthoodanalogchemical structure functionchronic infectiondata integrationdesigndesigningdetermine efficacydevelopmentaldrug/agenteffective therapyeffective treatmentefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationevaluate efficacyexamine efficacyexperienceflexibilityflexibleheavy metal Pbheavy metal leadimmune functionimmunological statusin vivoin vivo evaluationin vivo testinginhibitorintervention therapymachine learning based modelmachine learning modelmetermouse modelmurine modelnovelorgan allograftorgan graftorgan xenograftpersistent infectionpharmacologicpre-clinical developmentpreclinical developmentpreservationpreventpreventingprospectivereceptorscaffoldscaffoldingstructure function relationshiptargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmentvirtualvision impairmentvision lossvisual functionvisual lossvisually impaired
Description preview
PROJECT SUMMARY
Zero effective options exist for treating individuals who are chronically infected with the protozoan parasite
Toxoplasma gondii (Tg) as a source of reactivated toxoplasmosis. Reactivated Tg infection in the retina is a
leading cause of infectious posterior uveitis, impairing the vision of approximately 3,600 Americans annually.…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click